Nektar Therapeutics News

Shares of Nektar Therapeutics traded down 0.86% during mid-day trading on Thursday, hitting $6.91. Nektar Therapeutics has a one year low of $4.07 and a one year high of $10.83. The company's market cap is $792.0 million.

Shares of Nektar Therapeutics traded down 0.86% during mid-day trading on Thursday, hitting $6.91. Nektar Therapeutics has a one year low of $4.07 and a one year high of $10.83. The company's market cap is $792.0 million.

Nektar Therapeutics opened at 6.61 on Wednesday. Nektar Therapeutics has a 52-week low of $4.07 and a 52-week high of $10.83. The company's market cap is $757.6 million.

SAN FRANCISCO, May 2, 2012 /PRNewswire/ -- Nektar Therapeutics today reported its financial results for the first quarter ended March 31, 2012.

Financial and Strategic SWOT Analysis Review Summary Nektar Therapeutics is a bio-pharmaceutical company involved in the discovery and development of a pipeline of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs.